Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1

Inclusion criteria

• Written informed consent obtained prior to study entry including informed consent for molecular genetic analysis concerning candidate genes relevant for pharmacokinetics and pharmacodynamics of the study medication.
• Both genders (male and female), as far as feasible, in each of the 3 OCT1 genotype groups, an equal proportion of males and females will be included.
• Healthy adults aged ≥18 to < 50 years
• Body weight not less than 48 kg and body mass index (BMI) not less than 17 kg/m² and not greater than 32 kg/m².
• Willingness to meet the study instructions and to co-operate with the study personal
• No clinically relevant pathological findings in any of the investigations at the screening visit. Minor deviations of laboratory values from the normal range may be accepted, if judged by the investigator to have no clinical relevance
• Systolic blood pressure ≤ 140 mmHg and ≥ 100 mmHg, diastolic blood pressure ≤ 90 mmHg and ≥ 60 mmHg and heart rate ≤ 90 bpm and ≥ 50 bpm at screening visit
• Female subjects will only be included if they express their willingness not to become pregnant during the entire study period by practicing abstinence or reliable methods of contraception as specified in the respective protocol section.

Exclusion criteria

• Unwillingness or inability to give informed consent
• Involvement in the planning and conduct of the study (applies to staff directly employed at the study site / department)
• Participation in a clinical study or use of any other investigational or non-registered drug or vaccine during the study period or within 30 days preceding the first dose of study drugs.
• Blood, plasma or thrombocyte donation during the last 15 days prior to application of the test drugs.
• Any planned surgical treatment during the last 14 days prior and 14 days after the application of the test drugs.
• Known pregnancy or lactation period
• Any relevant pathological findings in any of the investigations at the screening visit including significant abnormalities as result of the medical-screening-laboratory-analysis, especially of the liver and kidney related parameters unless judged as medically irrelevant.
• QTcF > 450 ms in screening ECG
• Systolic blood pressure > 140 mmHg and < 100 mmHg, diastolic blood pressure > 90 mmHg and < 60 mmHg and heart rate > 90 bpm and < 50 bpm pre-dose at treatment period 4 (Amitriptyline)
• Any disease affecting liver or kidney or impairment of the liver or kidney-function
• Any cardiovascular disease
• Moderate to severe hypertension requiring medication therapy
• Bronchogenic asthma requiring constant drug treatment (stages 2 to 4 asthma)
• Diabetes mellitus, hyperthyroidism, hypothyroidism
• Glaucoma
• Symptomatic prostatic hyperplasia
• Any medical constellation that increases risk of bleeding, including chronic treatment with NSAID or COX-2 inhibitors
• History of alcohol and/or drug abuse and/or any abusive use of medicaments and/or positive drug screen
• History of any psychiatric or neurologic disorder. If there are any doubts at the screening visit on whether a person is suffering from a depression or not he or she will be excluded from the study or examined by a psychiatrist for clarification before inclusion.
• Any major gastrointestinal disease and any gastrointestinal disorder that is expected to significantly interfere with the pharmacokinetics of the study drug
• Gastrointestinal surgery which may interfere with the pharmacokinetics of the study drug (except appendectomy or herniotomy)
• Taking any medication within 7 days before or during the trial with the following exceptions: Oral contraceptive drug used will be documented but will not be an exclusion criterion. Other medication might be allowed on single case basis if considered necessary for the subject's safety and well-being and if interactions with the study medication are judged as irrelevant.
• Any other findings that could compromise the safety of the participant or the quality of the study-results
• Any known hypersensitivity or allergic reactions to any of the tested drugs
• History of severe hypersensitivity reactions and anaphylaxis
• Any other clinically significant diseases as judged by the investigator
• Body temperature > 37.5°C prior to drug application
• Known infection with HIV, Hepatitis B (HBsAg) or Hepatitis C (no laboratory diagnostics concerning these diseases will be performed within the present study)
• Inability or unwillingness to avoid any intake of alcohol from 48 h prior to until 72 hours after Investigational Medicinal Product (IMP) application application
• Pregnancy (positive pregnancy test performed prior to drug administration)